Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8341 to 8355 of 8903 results

  1. Social and emotional wellbeing in secondary education (PH20)

    This guideline has been updated and replaced by NICE guideline on social, emotional and mental wellbeing in primary and secondary education (NG223).

    Withdrawn guideline

  2. Immunisations: reducing differences in uptake in under 19s (PH21)

    This guideline has been replaced by NICE guideline NG218.

    Withdrawn guideline

  3. Mental wellbeing at work (PH22)

    This guideline has been updated and replaced by NICE guideline NG212.

    Withdrawn guideline

  4. Smoking: brief interventions and referrals (PH1)

    This guidance has been updated and replaced by NICE guideline NG92.

    Withdrawn guideline

  5. Maternal and child nutrition (PH11)

    This guideline has been updated and replaced by NICE guideline NG247.

    Withdrawn guideline

  6. Smoking: preventing uptake in children and young people (PH14)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline

  7. Stop smoking services (PH10)

    This guideline has been updated and replaced by NICE guideline NG92.

    Withdrawn guideline

  8. Social and emotional wellbeing in primary education (PH12)

    This guideline has been updated and replaced by the NICE guideline on social, emotional and mental wellbeing in primary and secondary education (NG223).

    Withdrawn guideline

  9. Gantenerumab for treating early Alzheimer's disease [ID6142]

    In development Reference number: GID-TA11269 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [ID6247]

    In development Reference number: GID-TA11251 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A [ID6312]

    In development Reference number: GID-TA11329 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [ID6678]

    In development Reference number: GID-TA11805 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued Reference number: GID-HST10007

    Highly specialised technologies guidance
    Discontinued

  14. Diabetic foot ulcers - new treatments [ID381]

    Discontinued Reference number: GID-TAG371

    Technology appraisal guidance
    Discontinued

  15. Laparoscopic radical hysterectomy for early stage cervical cancer (IPG338)

    This guidance has been updated and replaced by NICE HealthTech guidance 565.

    Withdrawn guidance